Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pricing Debate

Set Alert for Pricing Debate

Provider Consortium Will Try 'DIY' Solution To Generic Shortages, Pricing

Four health care systems representing 280 hospitals, with input from the US Department of Veterans Affairs, plan to make and sell their own generic drugs, focusing on those vitally needed by hospitals, with "appropriate" pricing.

Generic Drugs Pricing Debate Strategy

Latest From Pricing Debate

Outcomes-Based Contract By Harvard Pilgrim For Testing Could Be Model For Pharma

Prenatal testing services provider IIlumina commits to fund study on whether cost of expanding use of test is offset by reduction in spending on traditional screening practices.

Market Access Pricing Debate

Fight Brewing In Congress Over Part D Coverage Gap Discounts

Pricing Debate Legislation

An Image To Maintain: GAO Profit Picture Of Drug Industry Is Good To Store Away For Future Debates

Big pharma has been highly successful at changing the debate from the level of drug company profitability to who shares what part of dollars generated by drug sales, but there are still lingering efforts to define and describe overall drug industry profitability and put it in the overall context of the broader economy. These efforts are backburner for now but will come back at some point in the future. Some of the portrayals are friendlier to pharma than others.

Pricing Debate Policy

Drug Pricing Alliances Expand In Europe

Slovenia has joined the Valletta group, with Croatia set to follow. Meanwhile, Ireland has formally signaled its interest in joining the BeNeLuxA collaboration.
Government Payers Health Technology Assessment

Australian Bill Brings Further Price Cuts But Promise Of More New Drug Listings

A new bill just approved in Australia will introduce further price cuts in order to reap savings on the pharmaceutical bill, which will partly be used to fund the reimbursement listing of new drugs. The pharmaceutical industry will also benefit from a more predictable pricing environment, at least until 2022. 
Australia Pricing Debate

Generics, Budgeting, And The Stubborn Persistence Of Cost Savings

ANDA sponsors want inflation penalty in Medicaid repealed, but long struggle to eliminate IPAB shows just how hard it may be for generics industry to get that 'fix'.  
Generic Drugs Medicaid

At US Generic Association Annual Meeting, Worries About Sustainability

ANDA sponsors fret price erosion – and potential changes to 180-day exclusivity.
Pricing Debate Generic Drugs

Mehta Analysis: How Buffett And Friends Can Succeed, And How Pharma Would Be Affected

How Warren Buffett's company Berkshire Hathaway, Amazon and JPMorgan will address the challenge of creating affordable, quality healthcare for their employees in the US is far from clear, but they are intent on trying. Viren Mehta, founding partner of Mehta Partners LLC, considers what approach they might take to succeed where others have failed, and how such a course would impact on the pharma sector.

Private Payers Healthcare Systems

Medicare Part D Drug Price Policies May Offer Financial Trade-Offs

Higher manufacturer discounts required in donut hole under new budget law could offset somewhat by point-of-sale rebates in Part D, which are expected to be included in President Trump's FY 2019 budget proposal.

Medicare Pricing Debate
See All